Roche Teams With Spero To Target Gram-Negative Pathogens
Executive Summary
Roche gets an option to acquire program addressing drug-resistant gram-negative infections when it reaches IND-filing status. Spero is working on a novel target found originally in infected tobacco plants.
You may also be interested in...
Start-Up Quarterly Statistics, Q2 2014
Start-ups raised $893.9 million in Q2 2014, a 25% drop from last quarter’s record-setting $1.18 billion. Metabolic disease was the most prevalent therapeutic category involved in alliances; seven acquisitions were signed, five in the biopharma sector.
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
Law has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
CSL’s Hemgenix Gene Therapy Does Not Need A REMS, FDA Tells National Hemophilia Foundation
Peter Marks says labeling for CSL’s hemophilia B treatment adequately conveys its risks. He also denies NHF request that the label cite eligibility criteria used in clinical trials, responding to a citizen petition on the day the agency approves the therapy.